| http://www.w3.org/ns/prov#value | - Diseases such as CAPS, DIRA, IRAK-4 deficiency, and MyD88 deficiency illustrate the effects of a dysregulated IL-1 pathway and have spurred interest in the exploration of novel therapeutic targets that may include suppression of IL-1?? production and release, neutralization of secreted IL-1, inhibition of IL-1R signal transduction [4], and modification of inflammasome activation.
|
